Klivira
Request demo

Streamlining Tepezza Prior Authorization for Gastroenterology Practices

Gastroenterology practices manage a high volume of prior authorizations. Klivira helps streamline the Tepezza prior authorization process, ensuring timely patient access even for medications outside core GI indications.

Gastroenterology practices navigate a high volume of prior authorizations for biologics, procedures, and specialty drugs. While Tepezza (teprotumumab) is indicated for Thyroid Eye Disease, its authorization management may fall to PA teams within multispecialty health systems or for patients with complex comorbidities. This requires a robust, adaptable process to secure timely approvals, minimizing administrative burden on GI staff.

Understanding Tepezza Prior Authorization in a GI Context

While Tepezza is specifically indicated for Thyroid Eye Disease, gastroenterology practices, particularly within integrated health systems, often manage prior authorizations for a broad spectrum of specialty drugs. This necessitates that PA teams adapt to diverse clinical criteria and documentation requirements that extend beyond typical GI indications, demanding a flexible and efficient authorization workflow.

Key Documentation for Tepezza PA Approval

  • Diagnosis confirmation for Thyroid Eye Disease (TED)
  • Disease severity assessment (e.g., Clinical Activity Score, proptosis measurement)
  • Documentation of prior therapy history (e.g., corticosteroids, other immunosuppressants)
  • Comprehensive ophthalmologic and endocrinologic evaluation reports
  • Adherence to specific payer medical necessity criteria for TED
  • Relevant laboratory results (e.g., thyroid function, IGF-1 levels, if required by policy)

Navigating Payer Policies and Clinical Guidelines for Tepezza

Prior authorization for Tepezza relies on specific payer medical policies and clinical guidelines from relevant specialties, such as the American Thyroid Association or the American Academy of Ophthalmology. Gastroenterology PA teams must efficiently access and interpret these diverse criteria, which differ significantly from common ACG or AGA frameworks, requiring systems that can adapt to varied clinical contexts and policy updates.

Common Tepezza PA Denial Reasons for GI Practices

  • Incomplete or insufficient diagnostic documentation for Thyroid Eye Disease
  • Failure to meet payer-specific step therapy requirements for specialty biologics
  • Missing or inadequate disease severity assessment in clinical notes
  • Lack of clear clinical rationale for drug initiation or continuation
  • Administrative errors in patient demographic or insurance information

Klivira's Role in Automating Tepezza PA for Gastroenterology

Klivira provides a centralized platform that integrates with EMRs, offering automated workflows for high-volume PA categories. For complex specialty drugs like Tepezza, our system helps manage the intricacies of diverse payer policies, documentation requirements, and the nuances of medical vs. pharmacy benefit routing, irrespective of the drug's primary clinical specialty.

Seamless EMR Integration for Enhanced PA Efficiency

Klivira's SMART on FHIR integration ensures that critical patient data, including medication history and diagnostic reports, flows directly from the EMR to the PA request. This capability significantly reduces manual data entry, minimizes potential errors, and accelerates the Tepezza prior authorization process for gastroenterology practices, allowing staff to focus on patient care.

Frequently asked questions

Why would a GI practice need to manage Tepezza prior authorizations?

In multispecialty clinics or integrated health systems, prior authorization teams often centralize drug authorization for all specialties. Additionally, patients with complex comorbidities might receive care across various departments, requiring GI administrative staff to coordinate PAs for non-GI specific medications like Tepezza.

What specific challenges does Tepezza PA present compared to typical GI biologics?

Tepezza's indication (Thyroid Eye Disease) requires adherence to distinct clinical guidelines and documentation, differing from those for IBD biologics or Hep C DAAs. PA teams must be proficient in accessing and applying criteria from endocrinology or ophthalmology, rather than standard GI guidelines, and also navigate the medical vs. pharmacy benefit distinctions common to many specialty drugs.

How does Klivira help with payer-specific criteria for Tepezza?

Klivira maintains an extensive, up-to-date library of payer medical policies. Our platform automatically identifies and applies the correct, current criteria for Tepezza based on the patient's insurance plan, guiding the prior authorization coordinator through the exact documentation and steps required for submission.

Can Klivira integrate Tepezza PA into our existing EMR system?

Yes, Klivira offers robust EMR integration, including SMART on FHIR capabilities. This allows for seamless, secure data exchange, pulling necessary patient information directly from your EMR to populate Tepezza prior authorization requests, significantly minimizing manual input and reducing the risk of errors.

What kind of turnaround time improvements can we expect for Tepezza PA with Klivira?

Klivira automates many steps in the prior authorization process, from initial submission to status tracking and appeals management. By reducing manual tasks, ensuring accurate and complete submissions, and proactively identifying payer requirements, our platform significantly accelerates the overall turnaround time for complex specialty drug PAs like Tepezza.

Related coverage

Other tepezza prior authorization by payer

Other tepezza prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo